1.01
Actuate Therapeutics Inc Aktie (ACTU) Neueste Nachrichten
Actuate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes - Stock Titan
Actuate Therapeutics (NASDAQ: ACTU) narrows loss but warns on cash runway - Stock Titan
ETFs Investing in Actuate Therapeutics, Inc. Stocks - TradingView
Actuate Therapeutics Inc (ACTU) Stock News Today - TradingKey
Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Actuate Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACTU - TradingView
Rodman & Renshaw Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $6 - Moomoo
Actuate Therapeutics stock initiated with buy rating at Rodman & Renshaw - Investing.com
Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Actuate Therapeutics Inc (ACTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actuate Therapeutics Inc (ACTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actuate Therapeutics Inc (ACTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.170|Chg%:-0.010 - TradingKey
Actuate Therapeutics Inc (ACTU) Cash Flow - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.140|Chg%:-0.040 - TradingKey
Actuate Therapeutics Inc (ACTU) Balance Sheet - TradingKey
Actuate Therapeutics Inc (ACTU) Income Statement - TradingKey
Actuate Therapeutics Inc (ACTU) Institutional Confidence - TradingKey
Actuate Therapeutics Inc (ACTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.185|Chg%:-0.075 - TradingKey
Actuate Therapeutics Inc (ACTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Actuate Therapeutics Q1 2026 Earnings: EPS Miss and Pre-Revenue Status Weigh on StockGAAP Earnings Report - dars.gov.et
Actuate Therapeutics Inc. (ACTU) Q1 2026 Earnings: EPS Miss of 8.6% Reflects Continued Pre-Revenue Investment PhasePerformance Review - dars.gov.et
Actuate Therapeutics, Inc. Files Form 8-K: NASDAQ Compliance Update and Company Details (July 2026) - Minichart
Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Actuate Therapeutics (ACTU) Surges 17.8% as Momentum Builds After Support TestgetLinesFromResByArray error: size == 0 - dars.gov.et
ACTU Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Drives Stock RallyDividend Growth Analysis - dars.gov.et
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Dynamic Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000E Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2500 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Price to book forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Price to sales forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Number of shareholders of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Price to earnings forward of Actuate Therapeutics, Inc. – NASDAQ:ACTU - TradingView
Actuate Therapeutics (ACTU) Declines Sharply – Key Support Tested at $1.73Double Top - dars.gov.et
Actuate Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACTU) - TradingView
ACTU Forecast — Price Target — Prediction for 2027 - tradingview.com
Actuate Therapeutics (ACTU) Finds Its Footing Near Key Support After a Modest GainEarnings Beat Stocks - dars.gov.et
Actuate Therapeutics (ACTU) Holds Near Key Support After Modest GainIV Crush Alert - dars.gov.et
Actuate Therapeutics (ACTU) Gains 2.8% on Elevated Volume, Tests Key Resistance at $2.19Single Stock ETF - DonanımHaber
ACTU Q1 2026 Earnings: Wider-than-Expected Loss Despite Positive Stock ReactionFinancial Health Score - newsline.com
Actuate Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
ACTU Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Advances PipelineEarnings Volatility Report - newsline.com
Buy Rating Reaffirmed on Elraglusib Momentum and External Validation; $15 ACTU Price Target Maintained - TipRanks
H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion - Investing.com
H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion By Investing.com - Investing.com Canada
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):